Developmentally Informed Pharmacotherapy for Child and Adolescent Depressive Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 21, Issue 2, 2012, Pages 313-325

  Sakolsky, Dara ^a   Birmaher, Boris ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescents; Children; Major depressive disorder; Selective serotonin reuptake inhibitors; Venlafaxine

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; ADOLESCENT; AGITATION; AKATHISIA; ANXIETY DISORDER; APPETITE; ATAXIA; BALANCE DISORDER; BIPOLAR DISORDER; BLEEDING; CHILD; CHILL; CLONUS; CONFUSION; DEPRESSION; DEVELOPMENTAL STAGE; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXCITEMENT; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART RHYTHM; HUMAN; HYPERREFLEXIA; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAJOR DEPRESSION; MYALGIA; MYDRIASIS; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PARESTHESIA; PATIENT COMPLIANCE; PERIOPERATIVE BLEEDING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RELAPSE; RESTLESSNESS; REVIEW; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TACHYCARDIA; TORSADE DES POINTES; TREMOR; VERTIGO; VIVID DREAM; VOMITING; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER, MAJOR; DEVELOPMENTAL DISABILITIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SUBSTITUTION; EVIDENCE-BASED MEDICINE; HUMANS; LONG-TERM CARE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME;

EID: 84860307157     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2012.01.005     Document Type: Review

References (47)

1. Lewinsohn P.M., Rohde P., Seeley J.R. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 1998, 18(7):765-794.
2. Birmaher B., Arbelaez C., Brent D. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin North Am 2002, 11(3):619-637.
3. Birmaher B., Ryan N.D., Williamson D.E., et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996, 35(11):1427-1439.
4. Lewinsohn P.M., Rohde P., Seeley J.R., et al. Psychosocial functioning of young adults who have experienced and recovered from major depressive disorder during adolescence. J Abnorm Psychol 2003, 112(3):353-363.
5. Birmaher B., Brent D.A. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007, 46(11):1503-1526. Work Group on Quality I.
6. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297(15):1683-1696.
7. Emslie G.J., Rush A.J., Weinberg W.A., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997, 54(11):1031-1037.
8. Emslie G.J., Rush A.J., Weinberg W.A., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 2002, 54(11):1031-1037.
9. March J., Silva S., Vitiello B., et al. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2004, 45(12):1393-1403.
10. Mayes T.L., Tao R., Rintelmann J.W., et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine?. CNS Spectrums 2007, 12(2):147-154.
11. Bridge J.A., Birmaher B., Iyengar S., et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009, 166(1):42-49.
12. Cheung A.H., Emslie G.J., Mayes T.L. The use of antidepressants to treat depression in children and adolescents. CMAJ Can Med Assoc J 2006, 174(2):193-200.
13. Wagner K.D., Jonas J., Findling R.L., et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006, 45(3):280-288.
14. Emslie G.J., Ventura D., Korotzer A., et al. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009 Jul, 48(7):721-729.
15. Wagner K.D., Robb A.S., Findling R.L., et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004, 161(6):1079-1083.
16. von Knorring A.L., Olsson G.I., Thomsen P.H., et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006, 26(3):311-315.
17. Wagner K.D., Ambrosini P., Rynn M., et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003, 290(8):1033-1041.
18. Berard R., Fong R., Carpenter D.J., et al. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006, 16(1-2):59-75.
19. Emslie G.J., Wagner K.D., Kutcher S., et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006, 45(6):709-719.
20. Keller M.B., Ryan N.D., Strober M., et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001, 40(7):762-772.
21. Emslie G.J., Kennard B.D., Mayes T.L., et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008, 165(4):459-467.
22. Kennard B.D., Emslie G.J., Mayes T.L., et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry 2008, 47(12):1395-1404.
23. Findling R.L., McNamara N.K., Stansbrey R.J., et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006, 16(1-2):131-145.
24. Wilens T.E., Cohen L., Biederman, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002, 22(6):568-575.
25. Hyttel J., Bogeso K.P., Perregaard J., et al. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm 1992, 88(2):157-160.
26. Perel J.M., Axelson D.A., Rudolph G., et al. Steroselective pharmacokinetic/pharmacodynamic (PK/PD) of ± citalopram in adolescents, comparisons with adult findings [Abstract]. Clin Pharmacol Ther 2001, 69:30.
27. Alderman J., Wolkow R., Chung M., et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998, 37(4):386-394.
28. Axelson D.A., Perel J.M., Birmaher B., et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002, 41(9):1037-1044.
29. Heiligenstein J.H., Hoog S.L., Wagner K.D., et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol 2006, 16(1-2):207-217.
30. Sakolsky D.J., Perel J.M., Emslie G.J., et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression In Adolescents (TORDIA) Study. J Clin Psychopharmacol 2011, 31(1):92-97.
31. Emslie G., Kratochvil C., Vitiello B., et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006, 45(12):1440-1455.
32. Safer D.J., Zito J.M. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006, 16(1-2):159-169.
33. Wilens T.E., Wyatt D., Spencer T.J. Disentangling disinhibition. J Am Acad Child Adolesc Psychiatry 1998, 37(11):1225-1227.
34. Geller B., Fox L.W., Clark K.A. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994, 33(4):461-468.
35. Strober M., Lampert C., Schmidt S., et al. The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes. J Am Acad Child Adolesc Psychiatry 1993, 32(1):34-42.
36. Lake M.B., Birmaher B., Wassick S., et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000, 10(1):35-38.
37. Weinrieb R.M., Auriacombe M., Lynch K.G., et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Safety 2005, 4(2):337-344.
38. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006, 59(11):1046-1051.
39. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63(3):332-339.
40. Olfson M., Shaffer D., Marcus S.C., et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003, 60(10):978-982.
41. Gibbons R.D., Hur K., Bhaumik D.K., et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006, 163(11):1898-1904.
42. Valuck R.J., Libby A.M., Sills M.R., et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004, 18(15):1119-1132.
43. Gibbons R.D., Brown C.H., Hur K., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007, 164(9):1356-1363.
44. Schatzberg A.F., Haddad P., Kaplan E.M., et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry 1997, 7:5-10.
45. Baldwin D.S., Montgomery S.A., Nil R., et al. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007, 10(1):73-84.
46. Tint A., Haddad P.M., Anderson I.M. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008, 22(3):330-332.
47. Brent D., Emslie G., Clarke G., et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008, 299(8):901-913.